Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer

详细信息    查看全文

• 作者：Harumi Sakahara (A1)
  Shuhei Yamashita (A1)
  Kazunori Suzuki (A1)
  Michiko Imai (A1)
  Takashi Kosugi (A1)
  
• 关键词：Radioiodine therapy ; Nasolacrimal duct ; Epiphora
• 刊名：Annals of Nuclear Medicine
• 出版年：2007
• 出版时间：November 2007
• 年：2007
• 卷：21
• 期：9
• 页码：525-527
• 全文大小：256KB
• 参考文献：1. Zettinig, G, Hanselmayer, G, Fueger, BJ, Hofmann, A, Pirich, C, Nepp, J (2002) Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging 29: pp. 1428-32 CrossRef
  2. Kloos, RT, Duvuuri, V, Jhiang, SM, Cahill, KV, Foster, JA, Burns, JA (2002) Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 87: pp. 5817-20 CrossRef
  3. Shepler, TR, Sherman, SI, Faustina, MM, Busaidy, NL, Ahmadi, MA, Esmaeli, B (2003) Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg 19: pp. 479-81 CrossRef
  4. Burns, JA, Morgenstern, KE, Cahill, KV, Foster, JA, Jhiang, SM, Kloos, RT (2004) Nasolacrimal obstruction secondary to 131I therapy. Ophthal Plast Reconstr Surg 20: pp. 126-9 CrossRef
  5. Brockmann, H, Wilhelm, K, Joe, A, Palmedo, H, Biersack, HJ (2005) Nasolacrimal drainage obstruction after radioiodine therapy: case report and a review of the literature. Clin Nucl Med 30: pp. 543-5 CrossRef
  6. Bakheet, SM, Hammami, MM, Hemidan, A, Powe, JE, Bajaafar, F (1998) Radioiodine secretion in tears. J Nucl Med 39: pp. 1452-4
  7. Morgenstern, KE, Vadysirisack, DD, Zhang, Z, Cahill, KV, Foster, JA, Burns, JA (2005) Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in 131I-treated patients. Ophthal Plast Reconstr Surg 21: pp. 337-44 CrossRef
  
• 作者单位：Harumi Sakahara (A1)
  Shuhei Yamashita (A1)
  Kazunori Suzuki (A1)
  Michiko Imai (A1)
  Takashi Kosugi (A1)
  
  A1. Department of Radiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan
  

文摘

The objective of this study was to report three cases with an accumulation of 131I in the nasolacrimal duct after radioiodine therapy for papillary thyroid cancer. A whole-body scan was taken 3 days after the administration of 3.7?GBq of 131I. Single-photon emission computed tomography (SPECT)/CT images were added when the location of a focal tracer uptake was undetermined on whole-body scans. In case 1, a 62-year-old woman complained of epiphora of the left eye after nine radioiodine therapies with a cumulative dose of 31.08?GBq. The left nasolacrimal duct was visualized at her tenth treatment with 131I. In case 2, a series of three radioiodine therapies had been given to a 73-year-old woman with a cumulative dose of 11.1?GBq. The accumulation of 131I was noted in the left nasolacrimal duct at her fourth treatment. She complained of epiphora of the left eye. In case 3, bilateral nasolacrimal ducts were visualized at the second radioiodine therapy in a 75-year-old woman. The patient had received 3.7?GBq of 131I at the first therapy. She did not complain of epiphora. It is possible that radiation from 131I that is secreted in tears and/or actively accumulated in the nasolacrimal duct may induce nasolacrimal duct obstruction. 131I in tears would be responsible for the visualization of nasolacrimal duct in the first two cases. 131I actively accumulated in the nasolacrimal duct might have been visualized in the third case. In summary, 131I is excreted in tears and is actively accumulated in the nasolacrimal duct. Obstruction of the lacrimal drainage system could occur after high-dose radioiodine therapy.